Structure-based inhibitor design of VAP-1/SSAO for the treatment of respiratory dirsorders and other major inflammatory diseases

基于结构的 VAP-1/SSAO 抑制剂设计，用于治疗呼吸系统疾病和其他主要炎症性疾病

• 批准号: LP0669658
• 负责人: Em/Prof Jules Guss
• 金额: $ 21.25万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-02-28 至 2010-08-26
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0669658
• 关键词: Structure; based; inhibitor; design; VAP

Inflammatory diseases, such as asthma, rheumatoid arthritis and multiple sclerosis, are widespread and often poorly treated in Australia and elsewhere. Inhibitors of the recently studied VAP-1/SSAO protein are predicted to effectively treat the inflammation symptoms of one or more of these diseases. A structure-based approach to discover these new medicines should provide a means to identify patentable compounds, with high potency, efficacy and safety. If this approach is successful, an Australian pharmaceutical company will be one of the first to the market with this new medicine to treat these chronic diseases.

炎症性疾病，如哮喘、类风湿性关节炎和多发性硬化症，在澳大利亚和其他地方很普遍，而且往往治疗不力。最近研究的VAP-1/SSAO蛋白的抑制剂预计可有效治疗这些疾病中的一种或多种的炎症症状。以结构为基础的方法来发现这些新药应该提供一种手段来识别具有高效力，有效性和安全性的可专利化合物。如果这种方法取得成功，一家澳大利亚制药公司将成为首批向市场推出这种治疗这些慢性疾病的新药的公司之一。